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Abstract
Background: Targeted temperature management (TTM) of 32 to 34 °C has been the
standard treatment for out-of-hospital cardiac arrest since clinical trials in 2002 indicated
benefit on survival and neurological outcome. In 2013, a clinical trial showed no difference
in outcome between TTM of 33 °C and TTM of 36 °C. In this meta-analysis, we investigate
the evidence for TTM in animal models of cardiac arrest.
Methods:We searched PubMed and EMBASE for adult animal studies using TTM
as a treatment in different models of cardiac arrest or global brain ischemia
which reported neurobehavioural outcome, brain histology or mortality. We used
a random effects model to calculate estimates of efficacy and assessed risk of
bias using an adapted eight-item version of the Collaborative Approach to Meta-
Analysis and Review of Animal Data from Experimental Studies (CAMARADES)
quality checklist. We also used a scoring system based on the recommendations
of the Stroke Treatment Academic Industry Roundtable (STAIR), to assess the
scope of testing in the field. Included studies which investigated a post-ischemic
induction of TTM had their treatment regimens characterized with regard to
depth, duration and time to treatment and scored against the modified STAIR
criteria.
Results: The initial and updated search generated 17809 studies after duplicate
removal. One hundred eighty-one studies met the inclusion criteria, including
data from 1,787, 6,495 and 2,945 animals for neurobehavioural, histological and
mortality outcomes, respectively. TTM was favoured compared to control for all
outcomes. TTM was beneficial using short and prolonged cooling, deep and moderate
temperature reduction, and early and delayed time to treatment. Median [IQR] study quality
was 4 [3 to 6]. Eighteen studies checked seven or more of the eight CAMARADES quality
items. There was no clear correlation between study quality and efficacy for any outcome.
STAIR analysis identified 102 studies investigating post-ischemic induction of TTM,
comprising 147 different treatment regimens of TTM. Only 2 and 8 out of 147
regimens investigated comorbid and gyrencephalic animals, respectively.
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Conclusions: TTM is beneficial under most experimental conditions in animal models
of cardiac arrest or global brain ischemia. However, research on gyrencephalic species
and especially comorbid animals is uncommon and a possible translational gap. Also,
low study quality suggests risk of bias within studies. Future animal research should
focus on mimicking the clinical scenario and employ similar rigour in trial design to that
of modern clinical trials.
Keywords: Targeted temperature management, Hypothermia, Cardiac arrest, Global
ischemia, Animals, Meta-analysis
Introduction
Animal research has shown that body temperature may have an effect on the extent of
brain damage following global ischemia [1–5]. Hyperthermia is associated with in-
creased damage in animal models [2, 6]. A similar association between hyperthermia
and worse neurological outcome in several brain injuries, including cardiac arrest, has
been observed in humans [7, 8]. In contrast, hypothermia has been reported to have a
protective effect in several animal models [1, 5, 9, 10].
In 2002, two randomized clinical trials (RCT) testing the effects of hypothermia in
patients with out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation were
published [11, 12]. They showed improved neurological function [11, 12] and increased
survival [11] in patients cooled to 32 to 34 °C for 12 to 24 h compared to patients with
no temperature control. Hypothermia has since been the recommended treatment in
international guidelines [13]. A third RCT published in 2013 further investigated the
concept of hypothermia in adults with OHCA, irrespective of initial rhythm. The Tar-
geted Temperature Management (TTM) trial found no benefit from hypothermia at
33 °C compared to controlled temperature at 36 °C for several parameters: survival [14],
neurological function [14–16] and release of biomarkers [17, 18]. A similar pediatric
study reported no significant increase in survival with good functional outcome at 1
year with hypothermia [19]. In another study, neurological function and mortality was
comparable when adults were cooled for 24 and 48 h [20]. In addition, six RCTs inves-
tigating prehospital cooling found no benefit of an early induction of hypothermia [21–
26]. A recently published RCT, in patients with OHCA and in-hospital cardiac arrest
with nonshockable rhythms, compared a controlled temperature of 33 °C to a con-
trolled temperature of 37 °C and found that survival with good neurological outcome
was higher with the lower temperature of 33 °C, while overall mortality was similar be-
tween the groups [27]. Importantly, in 2015, the European Resuscitation Council and
American Heart Association updated their guidelines on post-resuscitation care to in-
clude an option for a constant target temperature between 32 °C and 36 °C [28, 29].
The difficulty in translating promising therapies from bench to bedside is hardly new.
Among others, the Stroke Treatment Academic Industry Roundtable’s (STAIR) and
Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimen-
tal Studies (CAMARADES) have developed recommendations for study design and
quality to foster translation of new drugs [30, 31].
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Objectives
To our knowledge, there is no pre-clinical meta-analysis studying the efficacy of TTM
in experimental models of cardiac arrest or global brain ischemia. Our aims of this
meta-analysis are to (i) assess the efficacy of TTM in animal models of cardiac arrest or
global brain ischemia (reported as neurobehavioural outcome, brain histology and/or
mortality), (ii) assess the experimental conditions modifying efficacy, (iii) assess the
quality of individual studies, and (iv) assess the scope of testing in this field. With the
results of this study, we hope to elucidate possible knowledge gaps in the translation
from animal studies to clinical trials.
Methods
The methods of this study followed those outlined in a pre-specified study protocol [32].
Departures from the protocol are described in the “Limitations” section and Additional file 1.
Search strategy and eligibility
EMBASE and PubMed were searched with no restriction to time of publication or lan-
guage. The search contained three blocks: (i) synonyms to cardiac arrest or ischemia
(broad search) AND (ii) synonyms to hypothermia or temperature manipulation (in title
and/or abstract) AND (iii) synonyms to brain or its relevant structures (broad search), see
Additional file 1 for details. The first database search was performed 29 August 2015, and
it was updated 23 September 2016. A hand search of references from the included studies
was performed as well as a hand search of five selected reviews [33–37].
Studies were included if they were controlled, induced global brain ischemia in an
adult (sexually mature) non-human animal (mammal), used TTM as a treatment, and
assessed neurobehavioural outcome, mortality or a histological assessment of neuronal
death/injury in brain tissues. Studies were excluded if they used historical controls, in-
duced TTM pharmacologically, used cooling/heating only to prevent spontaneous
temperature change without a corresponding control group, where data could not be
used for meta-analysis (e.g. no information on group size or variance), which treated
animals with therapies adjuvant to TTM, treated newborn animals, and investigated
deep hypothermic circulatory arrest or cardiopulmonary bypass to enable cardiothor-
acic surgery. Further details are given in the supplement.
Data extraction and outcome assessment
Studies were entered into EndNote X7 and exported to CAMARADES Data Manager
(Microsoft Access), which was used to screen abstracts and review studies in full text.
Two independent reviewers screened each abstract. HO, GT and HW performed this
screening. Studies which two reviewers agreed on to exclude were excluded, and the
remaining studies were reviewed in full text independently by HO and GT. Questions
regarding eligibility were solved by consulting TD, NN or JR. The references from in-
cluded studies and selected reviews were entered into Microsoft Excel. References
already screened and studies not mentioning a synonym to ischemia or a synonym to
TTM in the title were removed by HO. Abstracts of remaining studies were screened
by HO. Full-text review were performed independently by HO and GT.
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Data extraction were performed independently by HO and GT using a data extrac-
tion template (see Additional file 1). Disagreements were solved by discussion, and if
not, then with the assistance of TD. Software from CAMARADES-NC3Rs Preclinical
Systematic Review & Meta-analysis Facility (SyRF), available at app.syrf.org.uk, was used
for data extraction and synthesis.
Our primary outcome was neurobehaviour. Brain histology and mortality were
secondary outcomes. If more than one histological or neurobehavioural outcome
were reported from the same cohort of animals, we summarized these using fixed-
effects meta-analysis to provide a summary estimate of each outcome. When a sin-
gle control group served multiple treatment groups, the number of animals in the
control group was divided by the number of treatment groups which it served and
recorded as the actual number [38]. If outcome was measured serially, only the
final measure was extracted. Ordinal data was analyzed as continuous variables for
the purpose of the meta-analysis. If data were presented in graphical form only,
computerized ruler software was used to measure graphs (FlexRuler version 2.3,
DropFrame, 2015).
Individual studies were checked using an adapted version of the CAMARADES qual-
ity checklist [30], consisting of (i) publication in a peer-reviewed journal, (ii)
randomization to treatment or control, (iii) blinded induction of ischemia (i.e. conceal-
ment of treatment group allocation at time of induction of ischemia), (iv) blinded
assessment of outcome, (v) statement of inclusion and exclusion of animals from the
study, (vi) sample size calculation, (vii) statement of compliance with regulatory re-
quirements, and (viii) statement regarding possible conflicts of interest. One study
could check a maximum of eight items, indicating a potentially lower risk of bias com-
pared to a study checking zero items.
We used modified STAIR criteria to assess the scope of testing in the subset of
studies with post-ischemic induction of TTM. It is similar to the one constructed
by O’Collins et al. to evaluate neuroprotective drugs in models of stroke [31, 33].
Our criteria consisted of eight items: (i) laboratory setting—regimen tested in two
or more laboratories, (ii) animal species—regimen tested in lissencephalic (rodents
and rabbits) and gyrencephalic species, (iii) health of animals—regimen tested in
comorbid animals (hyperglycemic, aged, hypertensive), (iv) sex of animals—regimen
tested in male and female animals, (v) outcome measures—regimen evaluated with
both histology and neurobehaviour, (vi) long-term effect—regimen evaluated long-
term outcome (≥ 4 weeks with either histology, mortality or neurobehaviour), (vii)
route of delivery—regimen tested with two or more methods of TTM (e.g. intra-
vascular cooling, surface cooling), and (viii) injury model—regimen tested in two or
more models of global brain ischemia where at least one model of global ischemia
is accomplished by induced cardiac arrest. To visualize the scope of animal testing
of clinical strategies of TTM, we constructed three 3 × 3-matrixes (< 2, 2 to 6, > 6
h time to treatment post-ischemia), each with three pre-specified durations and
temperature intervals. Each regimen was checked against the STAIR criteria and
contributed to the score of a specific combination of time to treatment, duration
and depth of TTM. A specific combination could score from zero to eight, with
eight being the highest possible, indicating a more extensive scope of testing (for
details, see Additional file 1).
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Statistical analysis
For neurobehavioural and histological outcome, we used standardized mean difference
(SMD), where a value above zero is interpreted as favouring the intervention. For mor-
tality, we used logarithmic odds ratio, where a value above zero is interpreted as favour-
ing the intervention. We used a random effects model as we expected great inter-study
heterogeneity, and I square (I2) to measure heterogeneity for the global estimate of each
outcome. This analysis was performed in the Shiny app for SyRF [39]. Publication bias
was measured with funnel plot, Egger regression and trim and fill.
Stratified subgroup analysis was pre-specified and divided into two domains, study
design and quality, with 16 and 5 items, respectively (see Additional file 1 for details).
To account for multiple comparisons, we set a significance level at p < 0.01 for the
quality domain and p < 0.0031 for the design domain. The significance of differences
between n groups was measured by partitioning heterogeneity and by using Chi-square
test, n − 1 degrees of freedom.
Results
Study selection
There were 7048 and 10609 studies generated from PubMed and EMBASE, respectively.
The hand search of included articles and selected reviews generated 5939 and 975 studies,
respectively. After exclusion of 16353 and 1275 studies during abstract screening and full-
text review, respectively, a total of 181 studies were included in the meta-analysis (173
from database search, 8 from hand search), 102 of which investigated post-ischemic in-
duction of TTM and were included in the STAIR analysis (Fig. 1, see Additional file 1 for
the full list of references). Altogether, the studies described 779 comparisons of treatment
Fig. 1 PRISMA flow diagram
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and control (123, 481 and 175 comparisons of neurobehaviour, histology and mortality in
1787, 6495 and 2945 animals, respectively).
We consulted a veterinarian to confirm if swine reasonably could be considered sexually
mature on the basis of the reported weights; many studies were excluded as a result.
Study characteristics and quality
Neurobehavioural outcomes extracted were mostly overall performance categories (OPC)
and neurobehavioural deficit scores (NDS) but also tests such as open field (motor/anx-
ious behaviour) and Morris water maze (cognition/memory). The hippocampal CA1-area
was the most common histological area evaluated, comprising 59% of all histological com-
parisons. Histological evaluation differed in use of staining method (Hematoxylin & Eosin,
TUNEL, Cresyl violet and NeuN being common stains). Induced normothermia was by
far the most common way of managing temperature in the control group. Median [IQR]
times to outcome evaluation in days were 4 [3 to 14], 7 [4 to 7] and 5 [3 to 7] for neurobe-
havioural, histological and mortality outcomes, respectively. Median times to treatment in
minutes in relation to time of recirculation or return of spontaneous circulation (ROSC)
were 1 [− 4.4 to 8.4], 1 [− 20 to 30] and 1 [− 2.4 to 30] for neurobehavioural, histological
and mortality outcomes, respectively. Median depths of TTM in degrees Celsius were 33
[32 to 34], 33 [31.3 to 33.6] and 33 [32 to 33.5] for neurobehavioural, histological and
mortality outcomes, respectively. Lastly, median durations of TTM in hours were 3 [1.1 to
11], 1.9 [0.8 to 5.3] and 4.1 [1.2 to 23] for neurobehavioural, histological and mortality
outcomes, respectively.
The median number of items checked in the CAMARADES quality checklist was 4
[3 to 6]. Only three studies met all eight items, and 15 studies met seven items.
Efficacy and publication bias
TTM was favoured compared to control for all three outcomes. Global estimates of ef-
ficacy were 0.93 [95% CI 0.79 to 1.08] SMD for neurobehaviour and 1.52 [95% CI 1.42
to 1.63] SMD for histology. The logarithmic odds ratio was 1.03 [95% CI 0.84 to 1.21]
for mortality. There was substantial heterogeneity for neurobehavioural (I2 = 47%) and
histological (I2 = 62%) outcomes but not for mortality (I2 = 0.7%).
Trim and fill-analysis and Egger regression was consistent with the presence of publi-
cation bias for neurobehavioural and histological outcomes; however, estimates of effi-
cacy still significantly favoured TTM compared to control in Trim and Fill-analysis
(Fig. 2 and Additional file 1). No evidence of publication bias was found for the mortal-
ity outcome.
Aspects of study quality modifying efficacy
There was no clear correlation between effect size and total study quality (Fig. 3 and
Additional file 1). Reporting of randomization was not associated with differences in ef-
ficacy for neurobehavioural and mortality outcomes, but efficacy was lower in random-
ized studies reporting histological outcomes (Fig. 4 and Additional file 1). Similarly,
reporting of the blinded assessment of outcome was not associated with differences in
neurobehavioural outcomes, but efficacy was lower in blinded studies reporting histo-
logical outcomes.
Olai et al. Intensive Care Medicine Experimental             (2020) 8:3 Page 6 of 16
Aspects of study design modifying efficacy
TTM was superior to control under most experimental conditions. The control proced-
ure was not significantly favoured for any subgroup (see forest plot in Fig. 4 and Add-
itional file 1). There were few clear findings relating to dose or aspects of study design
which were observed across all three outcomes; one more robust finding was that in-
duction of TTM before recirculation or ROSC was more effective than when induction
occurred after ischemia, although this too showed efficacy across all outcomes (Fig. 4
and Additional file 1). A longer post-ischemic delay of TTM was not clearly less effect-
ive than early post-ischemic induction. For the histological outcome, maximal efficacy
was seen at around 31 °C, but this was not seen for neurobehaviour and mortality.
However, across all outcomes, target temperatures closer to normothermia tended to
perform less well. A prolonged duration of TTM appeared to increase efficacy for
histological outcomes, but this was not seen for the other two outcomes. Since surface
cooling was used in most studies, a comparison between cooling methods was consid-
ered less meaningful. TTM was beneficial for all durations of ischemia, and no clear
difference of efficacy was seen between shorter and longer durations of ischemia.
Outcome evaluation at 4 weeks or later did not reveal any coherent trend for efficacy
across outcomes; TTM was more beneficial in histological outcome and less so in neu-
robehavioural. TTM was beneficial in both gyrencephalic (mostly dogs) and lissence-
phalic (rodents and rabbits) species. Comorbid testing was rarely reported, comprising
2%, 3% and 2% of comparisons for neurobehavioural, histological and mortality out-
comes, respectively, without clear evidence for the efficacy of TTM in these animals.
STAIR analysis
One hundred two studies with post-ischemic induction of TTM described 147 different
regimens of TTM with respect to post-ischemic time to treatment, duration and depth.
Fig. 2 Funnel plot and Trim and Fill analysis of neurobehavioural outcome. Open circles are missing studies
according to Trim and Fill-analysis. Estimate of efficacy with missing studies included: 0.76 SMD [95% CI 0.59
to 0.93]. Efficacy without missing studies: 0.93 SMD [95% CI 0.79 to 1.08]. Standardized mean difference = SMD.
Standard error = SE. Confidence interval = CI
Olai et al. Intensive Care Medicine Experimental             (2020) 8:3 Page 7 of 16
Most (86%) regimens of TTM were administered within 2 h of ischemia, and most fre-
quently (49%) to a depth between 29 and 34 °C and for a duration shorter than 8 h
(Table 1). Forty percent of regimens used a model of induced cardiac arrest rather than
selective arrest of cerebral circulation. Animals with comorbidities and gyrencephalic
animals were used in 1% and 5% of regimens, respectively. TTM was induced by sur-
face cooling alone in 82% of regimens, and 19% of regimens assessed outcome at 4
weeks or later.
Discussion
The quantitative results from this meta-analysis suggest that TTM, as a treatment in
animal models of cardiac arrest, is beneficial with regard to clinically relevant outcomes
such as neurobehaviour and mortality but also brain histology under most experimental
conditions. Substantial between-study heterogeneity and generally low to moderate
study quality require these results to be interpreted with considerable caution. The de-
scriptive part of our study reveals that an extensive range of experiments have been
performed but also suggests some overlooked aspects which might be relevant for
translation to the clinical setting.
Fig. 3 Number of study quality checklist items scored and point estimates of SMD with 95% confidence intervals (CI)
for neurobehavioural outcome. Low numerical checklist score on x axis indicates higher risk of bias. Shaded area is the
95% CI of the global estimate. Thickness of bar reflects number of contributing comparisons. Score ranging from a
minimum of 0 to a maximum of 8. SMD = standardized mean difference
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Fig. 4 (See legend on next page.)
Olai et al. Intensive Care Medicine Experimental             (2020) 8:3 Page 9 of 16
Study quality
We expected that measures to minimize bias might reduce the efficacy of TTM. This
was only evident for randomization procedures and blinded outcome assessment of the
histological outcome, similar to the results in another preclinical meta-analysis for
stroke models [40]. We were somewhat surprised that no convincing decrease of effi-
cacy was observed with increasing total study quality. However, a “meta”-meta-analysis
investigating the effect on outcome by total study quality showed no difference between
high- and low-quality studies [41], and it has been argued that total study quality is to
be regarded as a checklist rather than a quantitative measure [41, 42].
Study design
No single, optimal regimen of TTM was apparent. Rather, regardless of timing, dur-
ation and depth, TTM was superior to control.
Studies on rodents with selective arrest of cerebral circulation have suggested that
post-ischemic induction of TTM has outcomes comparable to normothermic controls,
while pre- and intra-ischemic TTM are greatly beneficial [1, 2, 43–45]. This contrasts
with results from studies, claiming that longer durations of TTM are protective even
when administered post-ischemia and also at longer survival times [3, 46, 47]. Subse-
quent studies of rodents using induced cardiac arrest models have showed that longer
durations of TTM are needed when administered post-ischemia [48–51]. Studies on
dogs with cardiac arrest have showed benefits of TTM when induced at the start of
CPR, but when delayed only for 15 min post-ischemia, benefits were abolished [4, 5, 52,
53]. Our results support the superiority of TTM induced before recirculation or ROSC
but also show that post-ischemic induction seems beneficial.
Studies claiming a benefit of post-ischemic TTM have estimated a therapeutic win-
dow up to 4 to 12 h from recirculation or ROSC with decreasing efficacy with increas-
ing delay [3, 46–48, 54]. Our results support this fairly wide therapeutic window,
(See figure on previous page.)
Fig. 4 Forest plot for neurobehavioural outcome (SMD) and 95% confidence intervals (CI) for select subgroups.
Shaded area is the 95% CI of the global estimate. Percentage in parentheses is meta-analytic weight. “Unknown”
categories are omitted. Right column brackets are 95% CI’s. *p < 0.0031, #p < 0.01 and n.s (not significant) denote
between-group differences for the groups covered by the vertical line. Corresponding forest plots for histological and
mortality outcomes are in supplement. SMD = standardized mean difference
Table 1 STAIR analysis of 102 studies with post-ischemic induction of TTM, which described 147
different regimens. The score is presented as x (y), where x is the number of items checked and (y)
is the number of treatment regimens contributing to that score, where 8 is the highest possible
score. Empty boxes were not tested
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allowing a delay of more than 6 h post-ischemia for neurobehavioural and histological
outcomes and up to 4 h for mortality.
Most studies comparing short-term and long-term outcome showed decreasing effi-
cacy with time, some with significant protection compared to control [46, 47, 55] while
others did not show long-term protection of TTM [43, 56]. Our results are not entirely
consistent, with lower and higher estimates of efficacy of TTM seen for neurobeha-
vioural and histological outcomes, respectively, when evaluation is performed after 4
weeks. TTM is not significantly different from control when there is a late evaluation
of mortality.
When several depths of TTM were tested, a lower temperature around 30 to 33 °C
was sometimes favoured compared to “milder” TTM around 34 to 35 °C [2, 57–59],
but just as often there was no significant difference between lower and “milder” TTM
[60–62]. In the preclinical meta-analysis on TTM as treatment of ischemic stroke, effi-
cacy was greater at temperatures below 31 °C [40]. We found no such sweet spot of
depth except around 31 to 32 °C for the histological outcome.
As for duration of TTM, studies addressing this issue tended to favour longer TTM
typically around 24 h [63–65]. Our results showed no such trends except for the histo-
logical outcome where durations beyond 8 h showed increasing efficacy.
Since our meta-analysis could not confirm any intuitive dose-response relationships of
different aspects of TTM across outcomes—which we anticipated given the findings in
studies investigating dose-response—we cannot conclude on an optimal regimen of TTM.
STAIR analysis
Case studies of accidental hypothermia where patients survived prolonged no-flow states
when cooled to very low temperatures before cardiac arrest occurred, and the use of deep
hypothermic circulatory arrest in cardiothoracic surgery also enabling long periods of no-
flow otherwise impossible in normothermic subjects, demonstrate beyond doubt that pre-
ischemic induction of TTM has neuroprotective effects in humans [66–68]. A clinically
feasible regimen of TTM in victims of cardiac arrest is usually post-ischemic, or possibly
intra-ischemic. The testing of post-ischemic TTM in animal studies is extensive and
matches the regimens used in the three larger clinical trials [11, 12, 14]. The STAIR ana-
lysis also revealed a low use of comorbid animals (1%) and gyrencephalic species (5%). In
the clinical trials, patients were old and had comorbidities, with average ages of 64 [14],
59 [11] and 67 years [12]. Ischemic heart disease and diabetes were present in around 30%
and 10% in the TTM-trial and the HACA study. The few studies that evaluated animals
with comorbidities did not consistently favour TTM [69–72]. Outcome was evaluated at
6months in both the TTM-trial and the HACA study, a time point rare in animal studies;
only 14 of 481 histological comparisons were made at 6 months or later and no compari-
sons of neurobehaviour and mortality were made at this time.
Possible translational gaps
Many studies had been conducted to explore injury mechanisms, i.e. they were not pri-
marily designed to evaluate survival with good neurological function but focused on
cellular and molecular mechanisms responsible for neuronal injury. In these studies,
the models are often focused on a limited brain area (i.e. hippocampus CA1) and
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titrated to produce a minimal loss of animals and mortality is not regularly reported.
We suggest that the mechanistic studies are less relevant to the translation of TTM to
the clinic, compared to studies with a stated intent of clinical translation. It is difficult
to discern to what extent this contribution of mechanistic studies might skew the re-
sults of this meta-analysis, but we consider it a possible translational gap.
While clinically relevant aspects of experimental design have been evaluated separ-
ately, we did not find a single study using comorbid animals in a cardiac arrest model
with a post-ischemic delay of TTM and functional outcome assessment at around 6
months, mimicking the clinical scenario. Also, studies of gyrencephalic species (dogs
and swine) evaluated outcome relatively early at around 3 to 4 days, likely due to costs
of animal handling. A problem for future research could be that to simulate the high
rate of mortality of real-life cardiac arrest in larger, comorbid animal models would not
be considered ethical.
The STAIR analysis shows extensive testing, in particular of regimens with a time to
treatment of less than 2 h post-ischemia. The majority of these regimens are closer to
immediate induction than to 2 h. In the clinical setting, TTM is commonly induced
around 2 h post-ischemia [11, 20, 73]. Induction of TTM beyond 2 h is not equally well
tested, and here, comorbid and gyrencephalic testing is lacking. The predominant use
of very early induction of TTM in animal studies, rarely achieved in the clinical setting,
might also be a translational gap. However, quantitative subgroup analysis did show
benefit of TTM induced beyond 2 h.
Limitations
Most papers are not written with a future meta-analysis in mind. Therefore, to
characterize how TTM was delivered was sometimes difficult. This might have led to
errors in interpretation and data extraction. We believe the research field would benefit
from adhering to the Utstein-guidelines for laboratory cardiopulmonary resuscitation
research [74] and the development of a standardized format for describing TTM. A
standardized format of TTM could include calculations of the area under the curve to
estimate the “dose,” which would make comparisons of different regimens easier.
Induced normothermia was the most common method of managing the control ani-
mals. Studies differed in how long they controlled and registered temperature. Late
temperature fluctuations after the end of registration are possible confounders in many
experiments [75] and subsequently in this meta-analysis. There is also an ongoing dis-
cussion whether a controlled temperature of 36 °C is to be regarded as a very mild form
of hypothermia rather than normothermia, which if true, would change the interpret-
ation of a majority of animal research [76].
We were fairly liberal in our interpretation of processes of randomization (46%) and
blinding of outcomes (59%), only requiring a simple statement, which might have led
to overestimation. Demanding more detail would have drastically decreased the num-
ber of studies checking these items.
Contrary to the neurobehavioral and histological outcome, I2 was very low for the mor-
tality outcome, implying low study heterogeneity. This may reflect a “tuning” of study de-
signs to minimize the need for animals to be euthanized prior to the planned end of the
experiment, both for animal welfare reasons and to minimize attrition (animals not able
to contribute data for analysis). The impression during review, however, was that studies
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had substantial heterogeneity in the reported aspects of study design, so the lack of statis-
tical heterogeneity is somewhat surprising.
Although this study analyzes a large sample of studies, it does not provide a complete
view. Since the database search was updated, new studies have surely been published.
We were not able to retrieve all studies identified by the search; moreover, we did not
translate studies written in a non-English language, which might introduce bias to our
results. If data from a study were incomplete, we decided against contacting the authors
for clarification. Therefore, the results reflect the data possible to extract solely from
the studies as published. Other protocol deviations can be found in the supplement.
Since the publication of our protocol, new findings based on data from focal ischemia
experiments have been published [77], suggesting that normalized mean difference as
effect size and meta-regression produces higher statistical power than standardized
mean difference and partitioning heterogeneity. This might be applicable to global is-
chemia experiments, possibly limiting our results.
Lastly, the fairly wide inclusion criteria including many different species as well as dif-
ferent models of global brain ischemia catches the scope of testing while on the other
hand limits the quantitative analysis since the experimental settings are different and
not always comparable. Also, some aspects of study design, such as method of CPR,
were not recorded. A few studies used cardiopulmonary bypass to resuscitate animals
[4, 52, 53, 60], a factor that could influence our results.
Conclusions
The large body of quantitative data from this meta-analysis shows that TTM as a treat-
ment of cardiac arrest is favoured under almost all experimental conditions and for all
outcomes. However, a majority of animals were healthy rodents and many studies were
of low study quality increasing the risk of bias. Also, the large amount of study hetero-
geneity weaken the quantitative results overall. Clinical trials have used the treatment
strategies suggested by animal experimentation, but it is possible that animal experi-
mentation has not simulated the clinical scenario well enough.
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